Log in to your Inderes Free account to see all free content on this page.
Annexin Pharmaceuticals
14.70 SEK
+1.38 %
Less than 1K followers
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Annexin Pharmaceuticals
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| growth-% | |||||||
| EBITDA | -28.1 | -43.5 | -51.2 | -40.7 | -44.2 | -50.5 | - |
| EBIT | -28.3 | -43.7 | -51.2 | -40.7 | -44.2 | -50.5 | -37.4 |
| Profit before taxes | -28.4 | -44.2 | -52.1 | -0.7 | -44.1 | -50.3 | -36.9 |
| Net income | -28.4 | -44.2 | -52.1 | -40.7 | -44.1 | -50.3 | -36.9 |
| EPS | -52.59 | -30.94 | -41.03 | -15.59 | -23.89 | -9.76 | -4.51 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | |||||||
| EBIT-% | |||||||
| ROE | -246.9 % | -214.4 % | -111.6 % | -135.1 % | -234.2 % | -366.5 % | -147.9 % |
| ROI | -176.9 % | -175.8 % | -98.8 % | -111.0 % | -164.6 % | -263.9 % | -122.3 % |
Login required
This content is only available for logged in users